The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.
Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.
BUCKSCO.Today on MSN2d
BioNTech Agrees to Pay $467M to Penn as Part of COVID-19 Vaccine Royalties SettlementUniversity of Pennsylvania will receive $467 million from BioNTech as part of a settlement in a lawsuit over COVID-19 vaccine royalties, writes John George ...
The BioNTech SE ADR BNTX inched 0.42% higher to $115.79 Friday, on what proved to be an all-around great trading session for ...
The Nobel Prize-winning scientific innovation underlying the COVID-19 vaccine proved to be a notable financial boon for the ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Big moves are shaking up BioNTech (NASDAQ:BNTX) this week, and investors are taking notice. The German biotech heavyweight ...
The University of Pennsylvania expects to receive $467 million from a German COVID-19 vaccine manufacturer after the pair ...
Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...
In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback